Posted 2 weeks ago

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC

ClinicalTrials.gov ID NCT04928846

Protocol number M18-868

Sponsor AbbVie